跳至主要内容
临床试验/NCT04776811
NCT04776811已完成不适用

Evaluation of Accuracy of Guardian Sensor 3 in Diabetes Patients on Peritoneal Dialysis

Elaine Chow1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2021年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Elaine Chow
入组人数
30
试验地点
1
主要终点
Mean absolute relative difference (MARD)

研究概览

简要总结

Assessment of performance (precision and accuracy) of Guardian Sensor™ 3 as compared with a gold standard reference laboratory method (YSI glucose) in diabetes patients on peritoneal dialysis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 or 2 diabetes mellitus diagnosed for at least 3 months
  • On continuous ambulatory peritoneal dialysis (CAPD) for at least 3 months
  • Male or female age ≥ 18 years old and ≤ 75 year old.
  • Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study.
  • Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices.
  • Willingness to abstain from swimming during their participation in the measurement phase.
  • In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate.
  • Written informed consent to participate in the study provided by the patient.

排除标准

  • Poorly controlled diabetes mellitus with HbA1c>11%
  • Peritonitis within 1 month
  • On icodextrin PD solutions
  • Planned for switching to hemodialysis or living donor transplant in future 3 months
  • Currently pregnant, as demonstrated by a positive pregnancy test at screening
  • Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.
  • Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.
  • Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.
  • Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis).
  • Have a known allergy to medical-grade adhesives, or known hypersensitivity to any of the products used in the study.
  • Blood donation of more than 500 ml within the last three months
  • Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection.
  • 13 Has a MRI scan, CT scan, or diathermy scheduled during the proposed study participation.
  • An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).
  • Women of reproductive potential who are unwilling to adopt contraceptive measures during the study period
  • Patients with history of pacemaker and prosthesis implantation.

结局指标

主要结局

Mean absolute relative difference (MARD)

时间窗: 5 minutes

MARD of sensor versus YSI glucose

次要结局

  • Hypoglycemia detection rates(15 minutes)
  • Consensus Error grid analysis(5 minutes)
  • Percent accuracy(5 minutes)
  • Median absolute relative difference (MedARD)(5 minutes)
  • Hyperglycemia detection rates(15 minutes)
  • User satisfaction(2 weeks)
  • Correlation between CGM metrics, HbA1c and fructosamine(2 weeks)

研究者

发起方
Elaine Chow
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Elaine Chow

Clinical Assistant Professor

Chinese University of Hong Kong

研究点 (1)

Loading locations...

相似试验